These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18502115)

  • 1. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands.
    Aben KK; Luth TK; Janssen-Heijnen ML; Mulders PF; Kiemeney LA; van Spronsen DJ
    Eur J Cancer; 2008 Aug; 44(12):1701-9. PubMed ID: 18502115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up.
    Schlesinger-Raab A; Treiber U; Zaak D; Hölzel D; Engel J
    Eur J Cancer; 2008 Nov; 44(16):2485-95. PubMed ID: 18783939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary resections for metastatic renal cell carcinoma in Iceland].
    Oddsson SJ; Isaksson HJ; Jonsson E; Einarsson GV; Gudbjartsson T
    Laeknabladid; 2008 May; 94(5):377-81. PubMed ID: 18460734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatments for metastatic kidney cancer.
    Mancuso A; Sternberg CN
    Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal tumour surgery in elderly patients.
    Roos FC; Pahernik S; Melchior SW; Thüroff JW
    BJU Int; 2008 Sep; 102(6):680-3. PubMed ID: 18410435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).
    Capitanio U; Perrotte P; Zini L; Jeldres C; Shariat SF; Isbarn H; Arjane P; Peloquin F; Pharand D; Montorsi F; Karakiewicz PI
    BJU Int; 2009 Sep; 104(6):795-9. PubMed ID: 19389018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of nephron-sparing surgery for T1b renal cell carcinoma.
    Joniau S; Vander Eeckt K; Srirangam SJ; Van Poppel H
    BJU Int; 2009 May; 103(10):1344-8. PubMed ID: 19040528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients.
    Marszalek M; Meixl H; Polajnar M; Rauchenwald M; Jeschke K; Madersbacher S
    Eur Urol; 2009 May; 55(5):1171-8. PubMed ID: 19232819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience.
    Liu Z; Lv J; Ding K; Fu Q; Cao Q; Wang F
    Int J Urol; 2009 Mar; 16(3):268-73. PubMed ID: 19087209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of local recurrence of renal cell carcinoma.
    Wiesner C; Jakse G; Rohde D
    Oncol Rep; 2002; 9(1):189-92. PubMed ID: 11748481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
    Patil S; Ishill N; Deluca J; Motzer RJ
    Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma.
    Jung EJ; Lee HJ; Kwak C; Ku JH; Moon KC
    Urology; 2009 Jan; 73(1):137-41. PubMed ID: 18950844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy.
    Haferkamp A; Pritsch M; Bedke J; Wagener N; Pfitzenmaier J; Buse S; Hohenfellner M
    BJU Int; 2008 May; 101(10):1243-6. PubMed ID: 18261150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma.
    Roos FC; Weirich J; Victor A; Elsässer A; Brenner W; Biesterfeld S; Hampel C; Thüroff JW
    BJU Int; 2009 Aug; 104(4):461-9. PubMed ID: 19338563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.